Global Colorectal Cancer Diagnostics and Therapeutics Market Report 2018-2023 - Segmented by Diagnostics, Therapeutics, and Geography - ResearchAndMarkets.com

DUBLIN--()--The "Global Colorectal Cancer Diagnostics and Therapeutics Market - Segmented by Diagnostics, Therapeutics, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The global market for colorectal cancer screening is expected to grow at a CAGR of 4.4% during the forecast period (2018-2023).

Colorectal cancer (CRC) accounts for over 9% of all cancer incidences, and it is a major cause of morbidity and mortality throughout the world. CRC is the second most common cause of cancer-related deaths in the United States. Moreover, there is an increase in the number of colorectal cancer screening tests, such as CT colonography, double-contrast barium enema, and biopsy test, which are being used for the treatment of people, thereby, driving the market for global colorectal cancer therapeutics in the near future. The other factors which also help in the growth of the market include technological advancements in radiology & chemotherapy, increasing cancer prevention initiatives, and others.

Geographically, North America holds the largest market share with respect to the demand and revenue. In 2017, based on the estimates by the American Cancer Society, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States. These estimates show that the colorectal cancer is increasing its prevalence in the United States which is leading to the growth of the market. The Asia-Pacific is also expected to show a strong growth pattern in the coming years, with China and India showing rapid progress.

Key Developments in the Market

  • May 2017: Novigenix signed a distribution agreement with Dr. Risch Medical Laboratory to access the Swiss German market for colox, its blood based colorectal cancer test

Key Topics Covered

1. Introduction

1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

5.1 Current Market Scenario

5.2 Porter's Five Forces Analysis

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

6.1 Market Drivers

6.2 Market Restraints

6.3 Opportunities

6.4 Key Challenges

7. Market Segmentation

7.1 By Diagnostics

7.2 By Therapeutics

7.3 By Geography

8. Competitive Landscape

8.1 Mergers & Acquisition Analysis

8.2 Agreements, Collaborations, and Partnerships

8.3 New Products Launches

9. Key Players

9.1 Abbott Diagnostics

9.2 Alere

9.3 Beckman Coulter

9.4 Clinical Genomics

9.5 Novigenix

9.6 Companion Dx

9.7 EDP Biotech

9.8 Epigenomics AG

9.9 Siemens Healthcare

9.10 Quest Diagnostics

9.11 Metabiomics Corporation

9.12 Volition Rx

9.13 List Not Exhaustive

10. Future of the market

For more information about this report visit https://www.researchandmarkets.com/research/5tlp7d/global_colorectal?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics, Colon Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Diagnostics, Colon Cancer Drugs